Abstract:BackgroundIdiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease of unknown cause, with limited therapeutic options and an urgent need to develop new treatment methods. However, there is still a lack of suitable inhaled drugs for the treatment of IPF due to non-specific side effects, inability to cross the pulmonary barrier, and inadequate management of heterogeneity. In this study, we hypothesized that tetrandrine liposomes (TET-LIPs) delivered by inhalation might have a direct targeting effect on lung tissue, effectively treat IPF and limit its adverse side effects on other organs.MethodsMorphology, particle size, zeta potential, and in vitro dissolution studies of the prepared TET-LIPs were performed. Blood aspartate aminotransferase (AST), alanine aminotransferase (ALT), Urea nitrogen (BUN), creatinine (Cr) were measured to determine the liver and renal function. Bleomycin-induced mice model of IPF was used to evaluate the in vivo pharmacodynamics of TET-LIPs. The levels of hydroxyproline, tumor necrosis factor (TNF-α), and transforming growth factor (TGF-β1) were examined by enzyme-linked immunosorbent assay (ELISA). Finally, alveolar lavage fluid lipid profiles were obtained by using ultra-performance liquid chromatography combined with quadrupole-Exactive Orbitrap mass spectrometry (UPLC-Q-Exactive Orbitrap MS).ResultsInhaled TET-LIPs significantly inhibited the progression of bleomycin-induced acute inflammation and pulmonary fibrosis in lung tissue. Furthermore, delivering the drug locally to the lungs showed little accumulation in the liver and kidneys after long-term inhalation and had a favorable safety profile. Interestingly, we observed a relationship between inhaled TET-LIPs and increased levels of triglycerides (TG), fatty acids (FA) while decreased levels of lysophosphatidylcholine (LPC) in BALF.ConclusionsOverall, as TET-LIPs were safe and well-tolerated in the BLM-induced mice model, tetrandrine encapsulation in liposomes could be an effective method for locally delivering to patients with IPF. Simultaneously, our findings revealed that various lipid metabolic disorders were linked to the early inflammatory phase of the fibrosis process, and the regulation of lipid metabolism may be one of the mechanisms to improve pulmonary fibrosis using TET-LIPs.

Single-Cell RNA-seq Provides New Insights into Therapeutic Roles of Thyroid Hormone in the Idiopathic Pulmonary Fibrosis

Single-Cell RNA Sequencing Provides New Insights into Therapeutic Roles of Thyroid Hormone in Idiopathic Pulmonary Fibrosis

Inhalation of Itraconazole Mitigates Bleomycin-Induced Lung Fibrosis Via Regulating SPP1 and C3 Signaling Pathway Pivotal in the Interaction Between Phagocytic Macrophages and Diseased Fibroblasts

Assessing the impact of triiodothyronine treatment on the lung microbiome of mice with pulmonary fibrosis

Triiodothyronine acts on DAO to regulate pulmonary fibrosis progression by facilitating cell senescence through the p53/p21 signaling pathway

[Research progress of thyroid hormone in pulmonary fibrosis]

TRβ activation confers AT2-to-AT1 cell differentiation and anti-fibrosis during lung repair via KLF2 and CEBPA

Role of transient receptor potential ankyrin 1 in idiopathic pulmonary fibrosis: modulation of M2 macrophage polarization

Exogenous Thymosin Beta 4 Suppresses IPF-Lung Cancer in Mice: Possibly Associated with Its Inhibitory Effect on the JAK2/STAT3 Signaling Pathway

METTL3‐Dependent YTHDF2 Mediates TSC1 Expression to Regulate Alveolar Epithelial Mesenchymal Transition and Promote Idiopathic Pulmonary Fibrosis

Integrated multiomic analysis identifies as a mediator of alveolar epithelial type II cell dysfunction in idiopathic pulmonary fibrosis

T3 Intratracheal Therapy Alleviates Pulmonary Pathology in an Elastase-Induced Emphysema-Dominant COPD Mouse Model

SLC15A3 plays a crucial role in pulmonary fibrosis by regulating macrophage oxidative stress

Deficiency of HtrA3 Attenuates Bleomycin-Induced Pulmonary Fibrosis Via TGF-β1/Smad Signaling Pathway.

Tanshinone IIA Alleviates Pulmonary Fibrosis by Inhibiting Pyroptosis of Alveolar Epithelial Cells Through the MAPK Signaling Pathway

Tacrolimus alleviates pulmonary fibrosis progression through inhibiting the activation and interaction of ILC2 and monocytes

Tetraethylthiuram disulphide alleviates pulmonary fibrosis through modulating transforming growth factor-β signalling

Inhalation of tetrandrine liposomes for the treatment of bleomycin induced idiopathic pulmonary fibrosis

Single-cell RNA sequencing reveals special basal cells and fibroblasts in idiopathic pulmonary fibrosis

Supramolecular Nanofibers Ameliorate Bleomycin-Induced Pulmonary Fibrosis by Restoring Autophagy

Vitamin D3 alleviates pulmonary fibrosis by regulating the MAPK pathway via targeting PSAT1 expression in vivo and in vitro